Solid TumoursNCT04529122
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
An observational study of Solid Tumours, run by Hoffmann-La Roche at 136 sites in 32 countries.
Trial summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumours
- How many people
- 7,864 participants
- Where
- 136 sitesin 32 countries
- Study dates
- 27 Aug 2020to 24 Apr 2026
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Male and Female adult participants who are diagnosed with solid tumour cancers (at any anatomical location) and at any stage of the disease who have undergone an NGS test.
Who may be able to join
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Who cannot join
- -Participant has a prior or current diagnosis of haematological malignancy
Trial locations and contacts
136 sites in 32 countries.
136 sites in 32 countries
France22 sites
Chu Amiens - Picardie
Amiens, 80054
Hopital Jean Minjoz
Besançon, 25030
Centre Hospitalier de Béthune-Beuvry
Béthune, 62408
Chu Brest - Hôpital Morvan
Brest, 29200
Centre Francois Baclesse
Caen, 14076
Centre Hospitalier de Chauny
Chauny, 02300
Centre Jean Perrin
Clermont-Ferrand, 63011
Groupe Hospitalier Public Du Sud De L'Oise GHPSO
Creil, 60109
Centre hospitalier universitaire Dijon-Bourgogne
Dijon, 21079
Hôpital Franco-Britannique- Fondation Cognacq-Jay
Levallois-Perret, 92300
Centre Oscar Lambret
Lille, 59020
Centre Leon Berard
Lyon, 69373
APHM
Marseille, 13385
Hopital de La Timone - CHU de Marseille
Marseille, 13385
Institut Régional du Cancer de Montpellier
Montpellier, 34298
Institut Curie
Paris, 75005
CH de Cornouailles
Quimper, 29107
Centre Eugene Marquis
Rennes, 35000
CHU Saint Etienne - Hôpital Nord
Saint-Etienne, 42055
Hôpital Privé de la Loire, Ramsay Saint Etienne
Saint-Etienne, 42100
CHI de Toulon - Hôpital Sainte Musse
Toulon, 83056
Gustave Roussy
Villejuif, 94800
United Kingdom12 sites
Blackpool Victoria Hospital
Blackpool, FY3 8NR
Bristol Haematology and Oncology centre
Bristol, BS2 8ED
Royal Sussex County Hospital
Eastbourne, BN2 1ES
Royal Devon & Exeter Hospital
Exeter, EX2 5DW
Gloucestershire Royal Hospital
Gloucester, GL1 3NN
Royal Surrey County Hospital
Guildford, GU2 7XX
St Georges University Hospitals NHS Foundation Trust
London, SW17 0RE
Freeman Hospital
New Castle Upon Tyne, NE7 7DN
Mount Vernon Hospital
Northwood, HA6 2RN
Musgrove Park Hospital
Somerset, TA1 5DA
Kings Mill Hospital
Sutton in Ashfield, NG17 4JL
Torbay Hospital
Torquay, TQ2 7AA
Germany10 sites
HELIOS Klinikum Bad Saarow
Bad Saarow, 15526
DRK Kliniken Berlin
Berlin, 12559
Universitätsklinikum Halle (Saale)
Halle, 06120
Asklepios Klinik Altona
Hamburg, 22763
Medizinische Hochschule Hannover
Hanover, 30625
SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III
Heilbronn, 74078
Praxis für Hämatologie, Onkologie und Palliativmedizin
Mönchengladbach, 41066
Klinikum am Steinenberg / Ermstalklinik
Reutlingen, 72764
Katharinenhospital Stuttgart
Stuttgart, 70174
Marien-Hospital Wesel
Wesel, 46483
India8 sites
Manipal Hospital
Bangalore, Karnataka, 560017
HealthCare Global Enterprises Limited
Banglore, Karnataka, 560027
Apollo Hospitals
Chennai, Tamil Nadu, 600035
Indo-American Cancer Hospital & Research Center
Hyderabad, Telangana, 500034
Tata Memorial Hospital
Mumbai, Maharashtra, 400012
MOC Cancer Care & Research Centre (Unit of Cellcure Cancer Centre Pvt Ltd)
Mumbai, Maharashtra, 400036
Max Super Speciality Hospital
New Delhi, National Capital Territory of Delhi, 110017
Bhaktivedanta Hospital and research institute
Thane, Maharashtra, 401107
Turkey (Türkiye)8 sites
Memorial Ankara Hastanesi
Ankara, 06520
Trakya University Medical Faculty
Edirne, 22030
Medicana International Zincirlikuyu Hospital
Istanbul, Enter Text, 34394
Ba?c?lar Medipol Mega Üniversite Hastanesi
Istanbul, 34214
Medicana International Atasehir Hospital
Istanbul, 34750
Medicana International Izmir Hospital
Izmir, 35170
Ac?badem Maslak Hastanesi Büyükdere
Sar?yer/?stanbul, 34457
Ac?badem Adana Hospital, Oncology Department
Seyhan/Adana, 01130
Colombia6 sites
Fundacion Cardioinfantil
Bogotá
Organizacion Sanitas Internacional
Bogotá
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Bogota, D.C., 110131
Fundacion Clinica Valle del Lili
Cali
Instituto Cancerología Medellin
Medellín, 050024
Clinica ASTORGA
Medellín, 50010
Brazil5 sites
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, 90035-001
D'or Instituto de Pesquisa e Educação
Rio de Janeiro
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, 01323-903
Beneficencia Portuguesa de Sao Paulo
São Paulo, 01321-00
Greece5 sites
General Hospital "G.Papanikolaou"
Asvestochóri, 570 10
Henri Dunant Hospital
Athens, 115 26
Alexandras General Hospital of Athens
Athens, 115 28
Metropolitan Hospital Fourth Oncology Clinic
Faliro, 185 47
Bioclinic Thessaloniki
Thessaloniki, 546 22
Ireland5 sites
Mid-Land Regional Hospital Tullamore
CO Offaly, R35 NY51
Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital
Dublin, 24
St Vincent'S Uni Hospital
Dublin, 4
St James's Hospital
Dublin, 8
Beacon Hospital
Dublin, D18 AK68
Serbia5 sites
University Hospital Medical Center Bezanijska kosa
Belgrade, 11080
Oncomed-System
Belgrade
SIRIUS Medical
Belgrade
Special hospital for internal diseases Vesalius
Belgrade
Oncology Institute of Vojvodina
Kamenitz, 21204
South Africa4 sites
IATROS International
Bloemfontein, 9301
Linksfield Oncology Inc.
Johannesburg, 2192
Medical Oncology Centre of Rosebank
Johannesburg, 2196
Wilgers Oncology Centre
Pretoria, 0001
Spain4 sites
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
Jaén, 23007
Hospital Clinico Universitario Virgen de la Victoria;Servicio de Oncologia
Málaga, 29011
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07014
Hospital Universitario Miguel Servet
Zaragoza, 50009
Estonia3 sites
East Tallinn Central Hospital
Tallinn, 11312
North Estonia Medical Centre Foundation
Tallinn, 13419
Tartu Uni Hospital
Tartu, 51014
Hungary3 sites
Orszagos Onkologiai Intezet
Budapest, 1122
Bács-Kiskun Vármegyei Oktatókórház
Kecskemét, 6000
Pécsi Tudományegyetem
Pécs, 7623
Lebanon3 sites
American University of Beirut - Medical Center
Beirut, 1107 2020
Hotel Dieu de France
Beirut, 2063 1111
Hammoud Hospital
Saida, 6520
Mexico3 sites
ONCARE Viaducto Napoles
Mexico City, Mexico CITY (federal District), 03810
The American British Cowdray Hospital/ Hospital Abc
Mexico City, 01120
Clínica Integral Internacional de Oncología S de RL de CV
Puebla City, Mexico CITY (federal District)
Philippines3 sites
Cebu Doctors' University Hospital
Cebu City, 6000
Metro Davao Medical and Research Center
Davao City, 8000
St Lukes Medical Center
Quezon City, 1102
Taiwan3 sites
Chang Gung Medical Foundation - Kaohsiung
Kaohisung, 833
Taipei Veterans General Hospital
Taipei, 112
Chung Gung Memorial Hospital
Taoyuan County, 333
Vietnam3 sites
Hanoi Oncology Hospital
Hanoi, 100000
K hospital
Hanoi, 100000
Ho Chi Minh City Oncology Hospital
Ho Chi Minh City
Argentina2 sites
Instituto Alexander Fleming
Buenos Aires, 1426
CEMIC
Buenos Aires, C1431FWN
Canada2 sites
Alberta Health Services
Calgary, Alberta, T2N 4N2
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6
Chile2 sites
Medicina de Precisión - Celerity
Las Condes, 7560908
Centro de Cancer Pontificie Universidad Catolica de Chile
Santiago, 8330074
Israel2 sites
Hadassah University Hospital - Ein Kerem
Jerusalem, 9112001
Sourasky / Ichilov Hospital
Tel Aviv, 6423906
Portugal2 sites
Hospital CUF Porto
Porto, 4100-180
IPO do Porto
Porto, 4200-072
Slovenia2 sites
University Clinic Golnik
Golnik, 4204
Institute of Oncology Ljubljana
Ljubljana, 1000
Thailand2 sites
Chulalongkorn Hospital
Bangkok, 10330
Faculty of Med. Siriraj Hosp.
Bangkok, 10700
United Arab Emirates2 sites
Tawam Hospital
Al Ain City, 15258
Mediclinic City Hospital
Dubai
Poland1 site
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie
Warsaw, 02-781
Saudi Arabia1 site
National Guard King Abdulaziz Medical City
Riyadh, 11426
About this study
Official title: A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
- Conditions
- Solid Tumours
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Measured: From date of registry entry until death, for up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2020
- Study start27 Aug 2020
- Primary completion24 Apr 2026
- Study completion24 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Solid TumoursStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 7,864 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04529122
- Sponsor's protocol ID
- MX39897
- Status last verified
- May 2026
- First submitted
- 25 Aug 2020
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Publications
Dienstmann R, Hackshaw A, Blay JY, Le Tourneau C. Core variables for real-world clinicogenomic data collection in precision oncology. ESMO Real World Data Digit Oncol. 2025 Feb 27;7:100117. doi: 10.1016/j.esmorw.2025.100117. eCollection 2025 Mar.
PubMed 41647341
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
- ClinicalTrials.gov ID
- NCT04529122
- Acronym / sponsor ID
- MX39897
- Conditions
- Solid Tumours
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7,864 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 27 Aug 2020 (actual)
- Primary completion
- 24 Apr 2026 (actual)
- Study completion
- 24 Apr 2026 (actual)
- First posted
- 27 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Male and Female adult participants who are diagnosed with solid tumour cancers (at any anatomical location) and at any stage of the disease who have undergone an NGS test.
Key inclusion criteria (4 listed)
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Key exclusion criteria (1 listed)
- -Participant has a prior or current diagnosis of haematological malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival
Time frame: From date of registry entry until death, for up to 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Derived from this study: PubMed 41647341Dienstmann R, Hackshaw A, Blay JY, Le Tourneau C. Core variables for real-world clinicogenomic data collection in precision oncology. ESMO Real World Data Digit Oncol. 2025 Feb 27;7:100117. doi: 10.1016/j.esmorw.2025.100117. eCollection 2025 Mar.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Related trials for Solid Tumours
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
136 sites in 32 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Solid Tumours, run by Hoffmann-La Roche at 136 sites in 32 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 136 sites in France, United Kingdom, Germany, India, Turkey (Türkiye) and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: From date of registry entry until death, for up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04529122, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.